Novel reaction to new cystic fibrosis medication Trikafta
Abstract We present a novel case of an urticaria multiforme‐type drug reaction to the new cystic fibrosis medication Trikafta (elexacaftor + tezacaftor + ivacaftor). Equipped with this information, clinicians may be more prepared to counsel and treat patients if they experience similar symptoms afte...
Main Authors: | Julian Stashower, Patrick Carr, Virginia Miller, Barrett Zlotoff |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-05-01
|
Series: | Clinical Case Reports |
Subjects: | |
Online Access: | https://doi.org/10.1002/ccr3.4116 |
Similar Items
-
Phenotyping Rare CFTR Mutations Reveal Functional Expression Defects Restored by TRIKAFTA<sup>TM</sup>
by: Onofrio Laselva, et al.
Published: (2021-04-01) -
Urticaria multiforme: A commonly misdiagnosed entity
by: Reena K Sharma, et al.
Published: (2019-01-01) -
Acquired Cold Urticaria vs. Autoinflammatory Diseases, Genetic and Clinical Profile and Differential Diagnosis: Study of a Cohort of Patients in a Tertiary Reference Centre
by: Gustavo Deza, et al.
Published: (2019-09-01) -
Allele-Specific Prevention of Nonsense-Mediated Decay in Cystic Fibrosis Using Homology-Independent Genome Editing
by: Steven Erwood, et al.
Published: (2020-06-01) -
Urticaria multiforme in a child with SARS-CoV-2 infection
by: Konrad Zawadka, et al.
Published: (2021-08-01)